Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02792725
Title Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.